Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Aringer

Showing results (151-160 of 216) with videos related to

Pageof 22
Sort By:
The Lancet. Microbe|April 5, 2021
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19Roman N Rodionov, Anne Biener, Peter Spieth, et al.
Rheumatology (Oxford, England)|November 11, 2025
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Eric F Morand, Richard Furie, Martin Aringer, et al.
Zeitschrift Fur Rheumatologie|July 26, 2023
[Discipline-specific assessment of the report of the German Society of Internal Medicine e.V. (DGIM) on depiction of the treatment landscape in the field of internal medicine in Germany by the German Society for Rheumatology e.V. (DGRh)]Jürgen Braun, Andreas Krause, Hendrik Schulze-Koops, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2018
Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell ProfilingMichelle P Ashton, Anne Eugster, Sevina Dietz, et al.
Arthritis Care & Research|July 26, 2018
Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young AdulthoodKirsten Minden, Gerd Horneff, Martina Niewerth, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Clinical and Experimental Rheumatology|July 15, 2020
ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritisChristof Specker, Annette Alberding, Martin Aringer, et al.
Rheumatology (Oxford, England)|July 9, 2025
Type I interferon limits interleukin-6 signaling in SLE through shedding interleukin-6 receptors]Martyna Hempel, Erik Klapproth, Annika Krause, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Arthritis and Rheumatism|April 29, 2008
Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical featuresEsther Jimenez-Boj, Nancy Kedersha, Makiyeh Tohidast-Akrad, et al.
Pageof 22

Showing results (151-160 of 216) with videos related to

Sort By:
Pageof 22
The Lancet. Microbe|April 5, 2021
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19Roman N Rodionov, Anne Biener, Peter Spieth, et al.
Rheumatology (Oxford, England)|November 11, 2025
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Eric F Morand, Richard Furie, Martin Aringer, et al.
Zeitschrift Fur Rheumatologie|July 26, 2023
[Discipline-specific assessment of the report of the German Society of Internal Medicine e.V. (DGIM) on depiction of the treatment landscape in the field of internal medicine in Germany by the German Society for Rheumatology e.V. (DGRh)]Jürgen Braun, Andreas Krause, Hendrik Schulze-Koops, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2018
Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell ProfilingMichelle P Ashton, Anne Eugster, Sevina Dietz, et al.
Arthritis Care & Research|July 26, 2018
Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young AdulthoodKirsten Minden, Gerd Horneff, Martina Niewerth, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Clinical and Experimental Rheumatology|July 15, 2020
ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritisChristof Specker, Annette Alberding, Martin Aringer, et al.
Rheumatology (Oxford, England)|July 9, 2025
Type I interferon limits interleukin-6 signaling in SLE through shedding interleukin-6 receptors]Martyna Hempel, Erik Klapproth, Annika Krause, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Arthritis and Rheumatism|April 29, 2008
Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical featuresEsther Jimenez-Boj, Nancy Kedersha, Makiyeh Tohidast-Akrad, et al.
Pageof 22